Illumina Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 11:45PM GMT
Ruizhi Qin - JPMorgan Chase & Co, Research Division - Analyst

All right. Good afternoon, everyone. Welcome to our next company presentation by Illumina. I'm Julia Qin, life science tools and diagnostics analyst at JPMorgan. And let me turn the stage over to Francis.

Francis A. deSouza - Illumina, Inc. - CEO & Director

Thanks, Julia, and the JPMorgan team for hosting us, and thank all of you for joining us today. I'm Francis deSouza, the CEO of Illumina.

As a reminder, our presentation today includes forward-looking statements, non-GAAP measures and reconciliations to GAAP measures. Please refer to our SEC filings for a presentation of risks. Also, please review our statements on the hold separate requirement related to GRAIL. GRAIL must be held and operated separately and independently from Illumina pursuant to the interim measures ordered by the European Commission, which prohibited our acquisition of GRAIL.

Today, I'll cover 3 areas in our presentation: first, a company overview, including preliminary 2022 results and 2023 guidance.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot